Informatics Support for Clinical Trial Operations DF/HCC has made great progress in developing informatics to support the clinical research process. Over the last five years DF/HCC institutions have invested over $15 M in new information systems that ? either directly or indirectly enhance the ability to do clinical research. The DF/HCC Clinical Trials Information Services team (CT IS), in collaboration with OPRS and QACT, has developed and maintained several computer software applications and databases to facilitate the conduct of oncology clinical trials. The current informatics staff dedicated to clinical trials in the IS department is 5.0 FTE staff members. We are requesting 1.0 new FTE for the Partners CT IS team to continue its robust support of the Clinical Trials Infrastructure and 0.5 FTE for BIDMC IS, which will enable us to support the majority of systems detailed below. This funding will be especially important in the implementation and maintenance of a new electronic data capture (eDC) product that will begin in 2005. We are also requesting the continuation of CCSG funding for 2 FTEs to maintain the Oncology Protocol System. The Clinical Trials Allocation Committee (which reviews revenue received from industry and distributes to DF/HCC institutions based on accrual) is investigating options for adding a charge-back to industry for our informatics infrastructure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-44
Application #
7726475
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
44
Fiscal Year
2008
Total Cost
$490,674
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252
Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:
Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991
Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187
Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950

Showing the most recent 10 out of 411 publications